Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Liabilities from Discontinued Operations (2023 - 2024)

Historic Liabilities from Discontinued Operations for NovaBay Pharmaceuticals (NBY) over the last 2 years, with Q4 2024 value amounting to $1.2 million.

  • NovaBay Pharmaceuticals' Liabilities from Discontinued Operations rose 7048.71% to $1.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.2 million, marking a year-over-year increase of 7048.71%. This contributed to the annual value of $1.2 million for FY2024, which is 7048.71% up from last year.
  • NovaBay Pharmaceuticals' Liabilities from Discontinued Operations amounted to $1.2 million in Q4 2024, which was up 7048.71% from $698000.0 recorded in Q4 2023.
  • In the past 5 years, NovaBay Pharmaceuticals' Liabilities from Discontinued Operations registered a high of $1.2 million during Q4 2024, and its lowest value of $698000.0 during Q4 2023.